Search - tctmd.com

Displaying 1 - 6 of 6

Sort: Relevancy | Date

TCT 235: Efficacy and Safety of Bivalirudin and Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients Who Underwent Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

Presentation TCT 2024

TCT 235: Efficacy and Safety of Bivalirudin and Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients Who Underwent Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

Presenter: Hamza Naveed

October 28, 2024

Pharmacology Review of Medications in the Cardiac Cath Lab ARCH 2019

Presentation ARCH 2019

Pharmacology Review of Medications in the Cardiac Cath Lab ARCH 2019

Presenter: Hannah Pope

April 11, 2019

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Presentation TCT 2018

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Presenter: George D. Dangas, Germano Di Sciascio, Anne Tavenier

September 21, 2018

Featured Trial of the Day: EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin vs. Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI...

Presentation TCT 2013

Featured Trial of the Day: EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin vs. Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI...

Presenter: Philippe Gabriel Steg

October 30, 2013

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.